# US 2026/0306551 A1 · Endothelial cells for treatment of gastrointestinal fistula

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0306551 A1
- Document ID: US20260306551A1
- Status: Published application
- Kind: A1
- Application number: 19/479,531
- Filed: 2024-04-29
- Published: 2026-10-08
- Earliest claimed: 2023-04-28
- Assignees: Angiocrine Bioscience, Inc.; Cornell University
- Applicants: Angiocrine Bioscience, Inc.; Cornell University
- Inventors: Paul William Finnegan; Jeffrey W. Milsom
- Web page: https://patentgrep.com/patent/US20260306551A1

## CPC

- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of endothelial cells for the treatment of gastrointestinal fistula and provides compositions and methods relating thereto. In some aspects of the present invention the endothelial cells are E4ORF1+ endothelial cells, such as E4ORF1+ human umbilical vein endothelial cells.

## Claims

### Claim 1

A method of treating a GI fistula in a human subject in need thereof, the method comprising administering to a human subject with a GI fistula a composition comprising E4ORF1+ human umbilical vein endothelial cells (E4ORF1+ HUVECs), wherein: (a) from about 5×106 to about 200×106 total E4ORF1+ HUVECs, or (b) from about 5×106 to about 120×106 E4ORF1+ HUVECs per cm of fistula length, are administered to the subject by local administration at the site of the GI fistula, thereby treating the GI fistula in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is also treated by performing fistulotomy.

### Claim 3

A method of treating a GI fistula in a human subject in need thereof, the method comprising administering an effective amount of a composition comprising E4ORF1+ HUVECs to a human subject with a GI fistula by local administration at the site of the GI fistula, wherein the subject is not treated by fistulotomy, thereby treating the GI fistula in the subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein: (a) from about 5×106 to about 200×106 total E4ORF1+ HUVECs, or (b) from about 5×106 to about 120×106 E4ORF1+ HUVECs per cm of fistula length, are administered to the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein: (a) from about 7.5×106 to about 30×106 total E4ORF1+ HUVECs, or (b) from about 7.5×106 to about 30×106 E4ORF1+ HUVECs per cm of fistula length, are administered to the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein: (a) about 15×106 to about 30×106 total E4ORF1+ HUVECs, or (b) about 15×106 E4ORF1+ HUVECs per cm of fistula length, are administered to the subject.

### Claim 7

The method of any of the preceding claims, wherein the administration of the E4ORF1+ HUVECs comprises depositing the E4ORF1+ HUVECs along the length of the GI fistula.

### Claim 8

The method of any of the preceding claims, wherein curettage of the GI fistula is performed prior to administration of the E4ORF1+ HUVECs.

### Claim 9 (depends on 8)

The method of claim 8, wherein administration of the E4ORF1+ HUVECs comprises distributing the E4ORF1+ HUVECs along the length of the curetted GI fistula.

### Claim 10 (depends on 8)

The method of claim 8, wherein the administration of the E4ORF1+ HUVECs comprises distributing half of the E4ORF1+ HUVECs along one side of the curetted GI fistula and half of the E4ORF1+ HUVECs along the opposite side of the curetted GI fistula.

### Claim 11

The method of any of the preceding claims, further comprising surgically closing the internal opening of the GI fistula.

### Claim 12

The method of any of the preceding claims, further comprising surgically closing the internal opening of the GI fistula using sutures.

### Claim 13 (depends on 12)

The method of claim 12, further comprising administering E4ORF1+ HUVECs submucosally around the surgically closed internal opening of the GI fistula.

### Claim 14 (depends on 13)

The method of claim 13, further comprising administering from about 15×106 to 30×106 E4ORF1+ HUVECs submucosally around the surgically closed internal opening of the GI fistula.

### Claim 15

The method of any of the preceding claims, comprising repeating the administration of E4ORF1+ HUVECs to the subject multiple times, wherein the time interval between administrations is from about 2 weeks to about 12 weeks.

### Claim 16 (depends on 15)

The method of claim 15, wherein the time interval between administrations is from about 4 weeks to about 10 weeks.

### Claim 17 (depends on 16)

The method of claim 16, wherein the time interval between administrations is from about 6 weeks to about 8 weeks.

### Claim 18 (depends on 15, 16, 17)

The method of any one of claims 15-17, wherein the administration of the E4ORF1+ HUVECs to the subject is repeated once.

### Claim 19 (depends on 15, 16, 17)

The method of any one of claims 15-17, wherein the administration of the E4ORF1+ HUVECs to the subject is repeated twice.

### Claim 20 (depends on 15, 16, 17)

The method of any one of claims 15-17, wherein the administration of the E4ORF1+ HUVECs to the subject is repeated three times.

### Claim 21 (depends on 15, 16, 17)

The method of any one of claims 15-17, wherein the administration of the E4ORF1+ HUVECs to the subject is repeated four times.

### Claim 22

The method of any one of the preceding claims, where the GI fistula is an enterocutaneous fistula.

### Claim 23

The method of any one of the preceding claims, where the GI fistula is an entero-enteral fistula.

### Claim 24

The method of any one of the preceding claims, where the GI fistula is an anal fistula, an anorectal fistula, an anovaginal fistula, an appendiceal fistula, a biliary fistula, a cecal fistula, a colonic fistula, a colorectal fistula, a colovesical fistula, a duodenal fistula, a duodeno-colic fistula, an enterovesical fistula, an esophageal fistula, a gallbladder fistula, a gastric fistula, a gastrocolic fistula, a gastrojejunocolic fistula, an ileal fistula, a jejunal fistula, an oral fistula, a pancreatic fistula, a rectal fistula, a rectovaginal fistula, or a salivary gland fistula.

### Claim 25

The method of any one of the preceding claims, where the GI fistula is an anal fistula.

### Claim 26

The method of any of the preceding claims, wherein the composition comprises E4ORF1+ HUVECs and one or more excipients suitable for administration to a human subject selected from the group consisting of diluents, buffers, salts, polysaccharides, proteins, and preservatives.

### Claim 27 (depends on 26)

The method of claim 26, wherein the composition comprises human serum albumin (HSA).

### Claim 28 (depends on 26, 27)

The method of claim 26 or claim 27, wherein the composition comprises Dextran40.

### Claim 29 (depends on 26, 27, 28)

The method of any one of claims 26-28, wherein the composition comprises up to about 0.25% DMSO.

### Claim 30 (depends on 26, 27, 28, 29)

The method of any one of claims 26-29, wherein the composition comprises HSA, Dextran40 and up to about 0.25% DMSO.

### Claim 31

The method of any of the preceding claims, wherein the composition is administered locally using a needle.

### Claim 32

The method of any of the preceding claims, wherein the composition is administered locally under imaging guidance.
